161 related articles for article (PubMed ID: 8990062)
1. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
Merello M; Nouzeilles MI; Arce GP; Leiguarda R
Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
[TBL] [Abstract][Full Text] [Related]
4. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
6. P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs.
Prabhakar S; Syal P; Srivastava T
Neurol India; 2000 Sep; 48(3):239-42. PubMed ID: 11025627
[TBL] [Abstract][Full Text] [Related]
7. Bilateral subthalamic stimulation effects on oral force control in Parkinson's disease.
Pinto S; Gentil M; Fraix V; Benabid AL; Pollak P
J Neurol; 2003 Feb; 250(2):179-87. PubMed ID: 12574948
[TBL] [Abstract][Full Text] [Related]
8. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
[TBL] [Abstract][Full Text] [Related]
9. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
Müller T; Benz S; Börnke C; Przuntek H
Acta Neurol Scand; 2004 May; 109(5):348-54. PubMed ID: 15080862
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
11. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
[TBL] [Abstract][Full Text] [Related]
12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine test in de novo Parkinson's disease.
Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
[TBL] [Abstract][Full Text] [Related]
14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
15. [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
Stocchi F; Ruggieri S; Baronti F; Bellantuono P; Brughita G; Antonini A; Bravi D; Agnoli A
Clin Ter; 1987 Jul; 122(2):83-8. PubMed ID: 2973904
[No Abstract] [Full Text] [Related]
16. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
17. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
18. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
[TBL] [Abstract][Full Text] [Related]
19. [Levodopa dependency in Parkinson's disease: case report and review].
Müller U; Reuter M; Hermann W; Gertz HJ
Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
[TBL] [Abstract][Full Text] [Related]
20. Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers.
Burleigh-Jacobs A; Horak FB; Nutt JG; Obeso JA
Mov Disord; 1997 Mar; 12(2):206-15. PubMed ID: 9087979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
